Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 1,743 trials

Heart Disease Treatment: Drug-Coated Balloon vs. Drug-Eluting Stents

We are comparing a new balloon treatment with standard stents for patients with heart disease at high risk of bleeding. The goal is to see if the new method is just as effective while requiring less blood-thinning medication.

Coronary Artery Disease>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Acetic Acid for Healing Skin Ulcers

We are studying whether acetic acid can help improve the healing of skin ulcers with biofilm compared to standard treatment. This trial will look at healing rates and safety over several weeks.

Skin Ulcer>2 yearsEfficacy phase (II)Standard MedicinesDermatology

Multiple Sclerosis: Frexalimab vs. Teriflunomide

We are studying a new medication, frexalimab, for adults with relapsing forms of multiple sclerosis. The goal is to see if it works better than teriflunomide in reducing relapses and improving quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Frexalimab for Nonrelapsing Secondary Progressive Multiple Sclerosis

We are studying whether frexalimab can help delay disability progression in adults with nonrelapsing secondary progressive multiple sclerosis. The trial also examines its effects on quality of life and safety.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Non-ST Elevation Acute Coronary Syndrome: Aspirin Omission Study

We are investigating if avoiding aspirin can reduce bleeding risks for patients with non-ST segment elevation acute coronary syndrome. The goal is to see if this approach is as effective as current treatments for heart issues.

Non-ST-Segment Elevation Acute Coronary Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Prostate Cancer: AMG 509 Treatment Study

We are testing a new drug called AMG 509 for men with metastatic castration-resistant prostate cancer. The study aims to evaluate its safety and how it may help manage this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Oncology

Advanced MTAP-null Solid Tumors: AMG 193 Treatment Study

We are studying the safety and effectiveness of AMG 193, both alone and with docetaxel, for adults with advanced MTAP-null solid tumors. This research aims to find better treatment options for these patients.

Advanced MTAP-null Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatologyOncology

Traumatic Brain Injury: Wharton's Jelly Stem Cells

We are investigating whether stem cells from umbilical cord tissue can help reduce inflammation and improve immune response after a traumatic brain injury. This study aims to find new treatment options for recovery.

Severe Traumatic Brain Injury (TBI)>2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineNeurology

Secukinumab: Long-Term Safety Study

We are evaluating the long-term safety of Secukinumab for patients who have previously participated in a related study. This trial will help us understand any potential side effects of continued treatment.

Psoriatic ArthritisAnkylosing SpondylitisNon-radiographic Axial Spondyloarthritis>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicineRheumatology

Intra-Hepatic Cholangiocarcinoma: New Treatment Approaches

We are studying a combination of treatments for patients with inoperable intra-hepatic cholangiocarcinoma. The goal is to see if these treatments can improve survival and quality of life.

Non-resectable Cholangiocarcinoma>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Type 2 Diabetes: Finerenone and SGLT2 Inhibitors

We are studying the effects of a new treatment combining finerenone with SGLT2 inhibitors for people with type 2 diabetes. The goal is to see if this combination improves heart and kidney health.

Type 2 DiabetesChronic Kidney Disease>2 yearsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyEndocrinologyNephrology

Fibrotic Lung Disease: Inhaled Treprostinil Study

We are evaluating the long-term safety of inhaled treprostinil for individuals with fibrotic lung diseases. This study is for those who have previously participated in related trials and need ongoing treatment.

Lung Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Head and Neck Cancer: Pembrolizumab with Radiotherapy

We are studying if adding radiotherapy to pembrolizumab helps patients with limited spread of head and neck cancer live longer and feel better. This trial focuses on those with a specific type of cancer and aims to compare treatment effects and safety.

Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Rosuvastatin for Preventing Venous Thromboembolism Recurrence

We are studying whether generic rosuvastatin can help prevent further blood clots in patients with a history of venous thromboembolism. We will also look at its safety and effects on bleeding and other vascular events.

Deep Vein ThrombosisPulmonary EmbolismVenous Thromboembolism>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyHematology

Cardiac Surgery: DOAC vs. Vitamin K Antagonist Study

We are studying the safety of two blood thinners for patients with atrial fibrillation after heart surgery. This research may help determine the best anticoagulation treatment for these patients.

Atrial Fibrillation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Spinal Muscular Atrophy: Risdiplam Treatment Study

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have received gene therapy. This research aims to see if early treatment can improve their condition.

Spinal Muscular Atrophy>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Aortic Stenosis: Protamine for Heart Procedure Safety

We are studying whether using protamine sulfate can reduce complications like strokes and bleeding during heart valve surgery. This trial is for patients with aortic stenosis undergoing transcatheter aortic valve implantation.

Cardiovascular Disorder>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Stomach and Pancreatic Cancer: ASP2138 Treatment Study

We are investigating the effects of ASP2138 alone and with other cancer treatments for adults with stomach, gastroesophageal junction, or pancreatic cancer. This study aims to see if it can improve treatment results.

Pancreatic CancerStomach CancerGastroesophageal Junction Cancer>2 yearsSafety phase (I)Oncology

Large Incisional Hernia: Botulinum Toxin A Injection Study

We are investigating whether injecting botulinum toxin A before surgery helps reduce complications and improve recovery for patients with large incisional hernias. This study compares the effects of BTA to a placebo injection.

Incisional Hernia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementGastroenterologyOrthopedics and Traumatology

GVHD Prevention in Elderly AML/MDS Patients: Thymoglobulin vs. Grafalon

We are comparing two treatments to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome receiving stem cell transplants. The goal is to find out which treatment leads to better outcomes after transplantation.

Acute Myeloid LeukemiaMyelodysplastic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematology